Masticatory Muscle Pain and Progressive Mouth Opening Limitation Caused by Amyotrophic Lateral Sclerosis: A Case Report

This article reports a case of masticatory muscle pain and progressive limited mouth opening secondary to amyotrophic lateral sclerosis (ALS), popularly known as Lou Gehrig’s disease. The symptoms were first mistaken as those of temporomandibular disorders, before fatty degeneration of all masticatory muscles were discovered on magnetic resonance imaging (MRI). ALS should be considered in the differential diagnosis process when the patient presents with longstanding progressive mouth opening limitation associated with pain. MRI could facilitate the diagnostic process.

1. Boillée S, Velde CV, Cleveland DW. ALS: A disease of motor neurons and their nonneuronal neighbors. Neuron 2006; 52:39–59.

2. Bruijn L, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004;27:723–749.

3. Roman GC. Neuroepidemiology of amyotrophic lateral sclerosis: Clues to etiology and pathogenesis. J Neurol Neurosurg Psychiatry 1996;61:131–137.

4. Logroscino G, Traynor BJ, Hardiman O, et al. Descriptive epidemiology of amyotrophic lateral sclerosis: New evidence and unsolved issues. J Neurol Neurosurg Psychiatry 2008;79:6–11.

5. Dworkin SF, LeResche L. Research Diagnostic Criteria for Temporomandibular Disorders: Review, criteria, examinations and specifications, critique. J Craniomandibular Disord 1992;6: 301–355.

6. Derogatis LR. SCL-90: Administration, Scoring and Procedure Manual-l for the R(Revised) Version. Baltimore: Johns Hopkins University School of Medicine, 1977.

7. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain 1992;50:133–149.

8. Ohrbach R, Granger C, List T, Dworkin S. Preliminary development and validation of the Jaw Functional Limitation Scale. Community Dent Oral Epidemiol 2008;36:228–236.

9. Brettschneider J, Kurent J, Ludolph A. Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev 2013;6:CD005226.

10. Ganzini L, Johnston WS, Hoffman WF. Correlates of suffering in amyotrophic lateral sclerosis. Neurology 1999;52: 1434–1440.

11. Newrick PG, Langton-Hewer R. Pain in motor neuron disease. J Neurol Neurosurg Psychiatry 1985;48:838–840.

12. Gordon PH. Amyotrophic lateral sclerosis: An update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging Dis 2013;4:295–310.

13. Braun MM, Osecheck M, Joyce NC. Nutrition assessment and management in amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am 2012;23:751–771.

14. Greenwood DI. Nutrition management of amyotrophic lateral sclerosis. Nutr Clin Pract 2013;28:392–399.

15. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003;60:1094–1097.

16. Gordon PH, Delgadillo D, Piquard A, et al. The range and clinical impact of cognitive impairment in French patients with ALS: A cross-sectional study of neuropsychological test per-formance. Amyotroph Lateral Scler 2011;12:372–378.

17. Abrahams S, Goldstein LH, Simmons A, et al. Word retrieval in amyotrophic lateral sclerosis: A functional magnetic resonance imaging study. Brain 2004;127:1507–1517.

18. Rabkin JG, Albert SM, Rowland LP, Mitsumoto H. How common is depression among ALS caregivers? A longitudinal study. Amyotroph Lateral Scler 2009;10:448–455.

19. Manfredini D, Borella L, Favero L, Ferronato G, Guarda-Nardini L. Chronic pain severity and depression/somatization levels in TMD patients. Int J Prosthodont 2010;23:529–534.

20. Guarda-Nardini L, Pavan C, Arveda N, Ferronato G, Manfredini D. Psychometric features of temporomandibular disorders patients in relation to pain diffusion, location, intensity and duration. J Oral Rehabil 2012;39:737–743.

21. Newrick PG, Langton-Hewer R. Motor neurone disease: Can we do better? A study of 42 patients. Br Med J (Clin Res Ed) 1984;289:539–542.

22. Mandler RN, Anderson FA Jr, Miller RG, et al. The ALS Patient Care Database: Insights into end-of life care in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:203–208.

23. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347:1425–1431.

24. Borasio GD, Voltz R, Miller RG. Palliative care in amyotrophic lateral sclerosis. Neurol Clin 2001;19:829–847.

25. de Almeida JP, Silvestre R, Pinto AC, de Carvalho M. Exercise and amyotrophic lateral sclerosis. Neurol Sci 2012;33:9–15.

26. Lewis M, Rushanan S. The role of physical therapy and occupational therapy in the treatment of amyotrophic lateral scler osis. NeuroRehabilitation 2007;22:451–461.

27. Manrique D. Application of botulinum toxin to reduce the saliva in patients with amyotrophic lateral sclerosis. Braz J Otorhinolaryngol 2005;71:566–569.

28. Galhardo AP, da Costa Leite C, Gebrim EM, et al. The correlation of research diagnostic criteria for temporomandibular disorders and magnetic resonance imaging: A study of diagnostic accuracy. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;115:277–284.